マウス心不全モデルにおける心拍数依存性拡張期機能の評価のためのペーシング制御手順

Executive Industry Relevance

Heart failure with preserved ejection fraction (HFpEF) presents a major translational challenge due to the complexity of diastolic dysfunction and the limitations of conventional preclinical assessment tools. This pacing-controlled protocol enables precise, heart rate-dependent evaluation of diastolic function in murine models, directly addressing the need for mechanistic de-risking and predictive confidence in early cardiovascular drug discovery. By isolating cardiac performance from confounding variables, the method strengthens target validation and informs risk-adjusted portfolio decisions.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of heart rate-dependent diastolic dysfunction in disease-relevant murine models.
• Supports mechanistic de-risking by isolating cardiac-specific effects from systemic influences.
• Improves predictive confidence for target validation in HFpEF research pipelines.

Screening & Assay Development

• Facilitates preparation of validated cardiac function assays for downstream compound screening.
• Delivers reproducible, quantitative pressure-volume loop outputs across controlled heart rate increments.
• Enables standardization of diastolic function assessment, supporting scalable screening workflows.

Translational & Preclinical Research

• Aligns preclinical cardiac phenotyping with human HFpEF pathophysiology by focusing on diastolic impairment.
• Provides continuity from early discovery through preclinical validation of cardiac targets.
• Supports risk-adjusted advancement decisions by quantifying heart rate-dependent dysfunction.

Pipeline & Workflow Integration

This protocol integrates into the discovery-to-preclinical continuum by enabling robust, quantitative assessment of diastolic function in murine HFpEF models.

• Discovery Biology: Supports hypothesis testing and mechanistic clarification of heart rate-dependent cardiac dysfunction.
• Screening: Provides assay-ready, reproducible pressure-volume loop data for compound evaluation.
• Analytics: Generates quantitative outputs such as Tau and EDPVR for comparative analysis across experimental conditions.
• Translational Research: Bridges preclinical findings with clinical HFpEF endpoints by modeling diastolic impairment under controlled pacing.
• Enterprise Reuse: Establishes a reusable platform for cardiac function assessment in diverse heart failure models.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in cardiac target validation.
• Operational Value: Enhances standardization, reproducibility, and scalability of diastolic function assays.
• Strategic Value: Informs go/no-go decisions and improves capital efficiency by de-risking early cardiac programs.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement of cardiovascular assets.

Implementation Considerations

• Requires expertise in murine cardiac surgery and pressure-volume loop analysis.
• Demands specialized instrumentation for atrial pacing and conductance catheterization.
• Necessitates cross-team standardization of data acquisition and analysis protocols.
• Adaptation may be needed for different heart failure models or pacing parameters.
• Potential limitations include anesthesia effects and technical variability in catheter placement.

Biopharma FAQs